Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Renal, Renal Metastatic
Status:
Open
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Eligible for screening study DCP 001
NCT#03793166
A031704 is reactivated to new patient registration (Step 1), effective March 26, 2021.